Astrana Health Q2 Revenue Surges 49%, Full-Year Adjusted EBITDA Guidance Raised
ASTH sits 89% above its 52-week low of $18.08.
Summary
Astrana Health posted Q2 2026 revenue of $972.5M (+49% YoY) and lifted its full-year adjusted EBITDA guidance to $255M–$280M, fueled by strong membership growth and operating leverage.
Key Events · Earnings and Guidance · ASTH
-
Q2 Revenue Up 49%
Total revenue reached $972.5 million, driven by a 48% increase in Care Partners revenue to $932.8 million.
-
Adjusted EBITDA Raised
Full-year 2026 adjusted EBITDA guidance was raised to $255–$280 million, up from the prior implied range, reflecting broad-based outperformance.
-
Net Income More Than Doubles
Net income attributable to Astrana rose 109% to $19.7 million; adjusted diluted EPS of $0.80 beat the year-ago $0.55 by 45%.
-
Operating Leverage Improves
G&A as a percentage of revenue fell 210 bps year-over-year to 5.6%, aided by AI-enabled tools and Prospect synergies.
Analysis · ASTH · Trade & Services
A standout second quarter saw revenue jump 49% to $972.5 million and adjusted EBITDA climb 43% to $68.9 million. Net income attributable to Astrana more than doubled, reaching $19.7 million. Reflecting confidence in sustained momentum, the company raised its full-year adjusted EBITDA guidance to $255–$280 million. The results highlight the scalability of its physician-centric, AI-enabled platform and the successful integration of the Prospect acquisition, with operating leverage improving as G&A fell to 5.6% of revenue from 7.7% a year ago.
At the time of this filing, ASTH was trading at $34.13 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $18.08 to $51.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.